All In Biotech

Drug Trial Radar · NCT07850999

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function

A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Oct 14, 2026

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Assembly BiosciencesIndustry
Sponsor type
Industry
First posted
Oct 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to assess the safety, tolerability and pharmacokinetics of ABI-6250 in participants with mild hepatic impairment compared with participants with normal hepatic function.

Conditions

  • Mild Hepatic Imparement

Interventions

  • ABI-6250Drug

    Participants will receive ABI-6250 0.5 mg QD over 10 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of ABI-6250.Time frame: From Day 1 to Day 35, at pre-specified timepoints.
  2. Apparent Terminal Elimination Half Life (t 1/2) of ABI-6250.Time frame: From Day 1 to Day 35, at pre-specified timepoints.
  3. Time to Cmax (Tmax) of ABI-6250.Time frame: From Day 1 to Day 35, at pre-specified timepoints.
  4. Area Under the Plasma Concentration-Time Curve (AUC) from time zero to 24 hours postdose (AUC0-24) of ABI-6250 on Days 1 and 10.Time frame: From Day 1 to Day 35, at pre-specified timepoints.
  5. Apparent Systemic Clearance (CL/F) of ABI-6250.Time frame: From Day 1 to Day 35, at pre-specified timepoints.
  6. Apparent Volume of Distribution (Vz/F) of ABI-6250.Time frame: From Day 1 to Day 35, at pre-specified timepoints.
  7. Adverse events (AEs).Time frame: From enrollment to Day 35.
  8. Incidence of Clinically Significant Clinical Laboratory Parameters Abnormality.Time frame: From enrollment to Day 35, at pre-specified timepoints.
  9. Incidence of Clinically Significant Vital Signs Abnormality.Time frame: From enrollment to Day 35, at pre-specified timepoints.
  10. Incidence of Clinically Significant 12-lead Electrocardiogram (ECG) Abnormality.Time frame: From enrollment to Day 35, at pre-specified timepoints.
  11. Incidence of Clinically Significant Physical Examination Abnormality.Time frame: From enrollment to Day 35, at pre-specified timepoints.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Zealand Clinical Research

    Auckland, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.